Skip to main content
HLNHaleon plcHold5.6·$9.82+4.47%
HoldModerate Confidence
Investment thesis

Haleon offers a financially sound consumer health franchise with strong margins and a favorable risk/reward setup, but a death cross and sustained negative price momentum block near-term entry; the thesis requires a technical reversal before the asymmetric upside becomes actionable.

Thesis pillars

  • Quality Margins PiotroskiStable
  • Death Cross Price MomentumStable
  • Asymmetric Upside Risk RewardStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Haleon plc (HLN) Stock Analysis

Recovery setup

HoldModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $9.82, but acceptable to hold if already in. Reason: Thin upside margin: 3.6%.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such... Read more

QualityF-score8 / 9FCF yield3.24%
IncomeYield1.97%Payout37.08%sustainable
Stop $9.44Target $10.17(analyst − 13%)A.R:R 0.3:1
Analyst target$11.69+19.0%5 analysts
$10.17our TP
$9.82price
$11.69mean
$14

Hold if already holding. Not a fresh buy at $9.82, but acceptable to hold if already in. Reason: Thin upside margin: 3.6%. Chart setup: Death cross but MACD improving, RSI 72. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-06
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jul 30, 202627d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Thin upside margin: 3.6%

Key Metrics

P/E (TTM)20.0
P/E (Fwd)16.2
Mkt Cap$43.2B
EV/EBITDA18.6
Profit Mgn15.1%
ROE10.3%
Rev Growth0.6%
Beta0.24
Dividend1.97%
Rating analysts26

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

IV76%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.0
Support Resistance
0.0
Gap
5.0
52w Position
7.5

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
3.0
Value Rank
4.6
Quality Rank
6.9
GatesA.R:R 0.3 < 1.5@spotDeath cross (50MA < 200MA)Momentum 6.6>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 27d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
72 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $8.77Resistance $9.82

Price Targets

$9
$10
A.Upside+3.6%
A.R:R0.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! asymmetry at 0.3 (below the engine's 1.5 threshold)@spot

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-30 (27d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HLN stock a buy right now?

Hold if already holding. Not a fresh buy at $9.82, but acceptable to hold if already in. Reason: Thin upside margin: 3.6%. Chart setup: Death cross but MACD improving, RSI 72. Maintain position. Not compelling to add more. Target $10.17 (+3.6%), stop $9.44 (−4.0%), A.R:R 0.3:1. Score 5.6/10, moderate confidence.

What is the HLN stock price target?

Take-profit target: $10.17 (+3.6% upside). Target $10.17 (+3.6%), stop $9.44 (−4.0%), A.R:R 0.3:1. Stop-loss: $9.44.

What are the risks of investing in HLN?

Thin upside margin: 3.6%.

Is HLN overvalued or undervalued?

Haleon plc trades at a P/E of 20.0 (forward 16.2). TrendMatrix value score: 5.3/10. Verdict: Hold.

What do analysts say about HLN?

26 analysts cover HLN with a consensus score of 4.0/5. Average price target: $12.

What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · KNSA (Kiniksa Pharmaceuticals Interna) · TEVA (Teva Pharmaceutical Industries ) · LNTH (Lantheus Holdings, Inc.)
Home Stocks HLN

Latest news

Latest News

Bez Kabli4d ago
Marketscreener.com5d agoProduct
Yahoo Finance11d ago
Bez Kabli11d ago
MarketBeat11d ago
Yahoo Finance4d agoProduct
TradingView4d ago
TradingView7d ago
TradingView9d ago
TradingView9d ago
TradingView9d ago
Bez Kabli1d ago
Marketscreener.com6d agoProduct
Bez Kabli7d ago
Stock Titan7d ago
DirectorsTalk Interviews7d ago
TradingView7d ago
The Globe and Mail9d agoAnalyst
Bez Kabli3d ago
Stock Titan3d ago
Loading more...